LncRNA HOTAIR Contributes to Sorafenib Resistance through Suppressing miR-217 in Hepatic Carcinoma

BACKGROUND: Sorafenib is a multi-target kinase inhibitor that has been approved as a unique target drug for the treatment of advanced hepatocellular carcinoma (HCC). However, due to the frequent occurrence of drug resistance, its treatment efficacy is often limited. The aim of this study was to expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaofeng, Zhang, Weichen, Ye, Yufu, Li, Hong, Cheng, Longyu, Zhang, Min, Zheng, Shusen, Yu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232684/
https://www.ncbi.nlm.nih.gov/pubmed/32462038
http://dx.doi.org/10.1155/2020/9515071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232684/
https://www.ncbi.nlm.nih.gov/pubmed/32462038
http://dx.doi.org/10.1155/2020/9515071

Ejemplares similares